Kimberly R. Kalli

10.8k total citations
101 papers, 5.5k citations indexed

About

Kimberly R. Kalli is a scholar working on Molecular Biology, Immunology and Reproductive Medicine. According to data from OpenAlex, Kimberly R. Kalli has authored 101 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 33 papers in Immunology and 33 papers in Reproductive Medicine. Recurrent topics in Kimberly R. Kalli's work include Ovarian cancer diagnosis and treatment (32 papers), Immune Cell Function and Interaction (18 papers) and Cancer-related molecular mechanisms research (16 papers). Kimberly R. Kalli is often cited by papers focused on Ovarian cancer diagnosis and treatment (32 papers), Immune Cell Function and Interaction (18 papers) and Cancer-related molecular mechanisms research (16 papers). Kimberly R. Kalli collaborates with scholars based in United States, Slovakia and Canada. Kimberly R. Kalli's co-authors include Lynn C. Hartmann, Keith L. Knutson, Ellen L. Goode, Ann L. Oberg, Gary L. Keeney, Marshall D. Behrens, William A. Cliby, Philip S. Low, Cheryl A. Conover and D J McKean and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Kimberly R. Kalli

101 papers receiving 5.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberly R. Kalli United States	46	2.2k	2.1k	1.6k	1.1k	1.0k	101	5.5k
Daniel Rosen United States	37	2.6k 1.2×	1.5k 0.7×	608 0.4×	1.0k 0.9×	1.0k 1.0×	87	4.9k
Silvana Canevari Italy	49	4.4k 2.0×	3.2k 1.5×	2.2k 1.4×	1.4k 1.3×	583 0.6×	227	8.7k
Y. Gloria Meng United States	31	4.8k 2.2×	2.2k 1.1×	3.0k 1.8×	948 0.9×	628 0.6×	48	8.6k
Stefania Bellone United States	41	1.8k 0.8×	2.4k 1.1×	1.4k 0.9×	761 0.7×	922 0.9×	155	5.4k
Kenjiro Sawada Japan	40	2.7k 1.2×	1.3k 0.6×	1.0k 0.6×	1.5k 1.3×	789 0.8×	137	5.0k
Anne‐Marie Mes‐Masson Canada	50	4.4k 2.0×	2.7k 1.3×	1.3k 0.8×	1.9k 1.7×	1.2k 1.1×	272	9.1k
Thierry Maudelondé France	41	2.2k 1.0×	2.2k 1.1×	537 0.3×	1.9k 1.7×	439 0.4×	125	5.1k
Karin Milde‐Langosch Germany	42	3.2k 1.5×	1.9k 0.9×	739 0.5×	1.8k 1.6×	429 0.4×	130	5.6k
Christina M. Annunziata United States	37	2.5k 1.1×	2.6k 1.2×	1.2k 0.7×	1.0k 0.9×	1.1k 1.0×	155	5.4k
Paulette Mhawech‐Fauceglia United States	35	1.9k 0.9×	2.0k 1.0×	1.6k 1.0×	689 0.6×	651 0.6×	126	5.0k

Countries citing papers authored by Kimberly R. Kalli

Since Specialization

Citations

This map shows the geographic impact of Kimberly R. Kalli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly R. Kalli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly R. Kalli more than expected).

Fields of papers citing papers by Kimberly R. Kalli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly R. Kalli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly R. Kalli. The network helps show where Kimberly R. Kalli may publish in the future.

Co-authorship network of co-authors of Kimberly R. Kalli

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly R. Kalli. A scholar is included among the top collaborators of Kimberly R. Kalli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly R. Kalli. Kimberly R. Kalli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kalli, Kimberly R., Matthew S. Block, Pashtoon Murtaza Kasi, et al.. (2018). Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research. 24(13). 3014–3025. 72 indexed citations

Lamichhane, Purushottam, Lavakumar Karyampudi, Barath Shreeder, et al.. (2017). IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Research. 77(23). 6667–6678. 122 indexed citations

Wang, Chen, Sebastian M. Armasu, Kimberly R. Kalli, et al.. (2017). Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. Clinical Cancer Research. 23(15). 4077–4085. 65 indexed citations

Leonard, Brandon, Gabriel J. Starrett, Matthew J. Maurer, et al.. (2016). APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research. 22(18). 4746–4755. 52 indexed citations

Li, Zheng, Matthew S. Block, Robert A. Vierkant, et al.. (2016). The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Tumor Biology. 37(10). 13279–13286. 41 indexed citations

Karyampudi, Lavakumar, Purushottam Lamichhane, James Krempski, et al.. (2015). PD-1 Blunts the Function of Ovarian Tumor–Infiltrating Dendritic Cells by Inactivating NF-κB. Cancer Research. 76(2). 239–250. 86 indexed citations

Hendrickson, Andrea E. Wahner, Kieran Hawthorne, Ellen L. Goode, et al.. (2015). Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecologic Oncology. 137(1). 77–85. 16 indexed citations

Kasi, Pashtoon Murtaza, Kimberly R. Kalli, Matthew S. Block, et al.. (2015). A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.. Journal of Clinical Oncology. 33(15_suppl). e14028–e14028. 7 indexed citations

Karyampudi, Lavakumar, Purushottam Lamichhane, Adam D. Scheid, et al.. (2014). Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody. Cancer Research. 74(11). 2974–2985. 120 indexed citations

10.

Carlson, Aaron, Matthew J. Maurer, Krista M. Goergen, et al.. (2013). Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention. 22(10). 1730–1735. 31 indexed citations

11.

Becker, Marc A., Sean C. Harrington, James Krempski, et al.. (2013). Dual HER/VEGF Receptor Targeting Inhibits In Vivo Ovarian Cancer Tumor Growth. Molecular Cancer Therapeutics. 12(12). 2909–2916. 7 indexed citations

12.

Charbonneau, Bridget, Ellen L. Goode, Kimberly R. Kalli, Keith L. Knutson, & Melissa S. DeRycke. (2013). The Immune System in the Pathogenesis of Ovarian Cancer. Critical Reviews in Immunology. 33(2). 137–164. 52 indexed citations

13.

Pulido, José S., Thomas J. Flotte, Harish Raja, et al.. (2013). Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation. Eye. 27(9). 1058–1062. 21 indexed citations

14.

Karyampudi, Lavakumar, Courtney L. Erskine, Matthew J. Maurer, et al.. (2010). A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a NovelIn vivoImmunodominant Epitope, HER-2/neu88-102. Clinical Cancer Research. 16(3). 825–834. 14 indexed citations

15.

Santisteban, Marta, Jennifer M. Reiman, Michael K. Asiedu, et al.. (2009). Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells. Cancer Research. 69(7). 2887–2895. 320 indexed citations

16.

He, Wei, Sumith A. Kularatne, Kimberly R. Kalli, et al.. (2008). Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor‐specific fluorescent ligands. International Journal of Cancer. 123(8). 1968–1973. 124 indexed citations

17.

Hurt, Elaine M., et al.. (2008). Expression of the ZEB1 (δEF1) transcription factor in human: additional insights. Molecular and Cellular Biochemistry. 318(1-2). 89–99. 47 indexed citations

18.

Haluska, Paul, Joan M. Carboni, David A. Loegering, et al.. (2005). BMS-554417, an inhibitor of the insulin-like growth factor I receptor and insulin receptor, inhibits proliferation and induces mitochondrial pathway-mediated apoptosis in cancer cell lines. Cancer Research. 65. 1191–1191. 2 indexed citations

19.

Hedin, Karen E., M P Bell, Kimberly R. Kalli, et al.. (1997). Delta-opioid receptors expressed by Jurkat T cells enhance IL-2 secretion by increasing AP-1 complexes and activity of the NF-AT/AP-1-binding promoter element. The Journal of Immunology. 159(11). 5431–5440. 59 indexed citations

20.

Kalli, Kimberly R., J M Ahearn, & D T Fearon. (1991). Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. The Journal of Immunology. 147(2). 590–594. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact